Stockscreener 앱 받기
87.05
0.24%
-0.49
전일 마감가:
$87.54
열려 있는:
$87.31
하루 거래량:
14.37M
Relative Volume:
1.23
시가총액:
$151.73B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
24.25
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
-6.96%
1개월 성능:
-15.11%
6개월 성능:
-29.88%
1년 성능:
-34.14%
1일 변동 폭
$86.16
$87.83
1주일 범위
$86.16
$93.72
52주 변동 폭
$86.16
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.11 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.23 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.72 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.96 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.88 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook - Traders Union
Bioabsorbable Stents Industry Projected to Grow at 10.2% CAGR, - openPR.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott gets FDA nod, CE mark for AI-enabled imaging device - MedTech Dive
Abbott Laboratories: performance and outlook - Business Recorder
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Motley Fool
Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Offers Growth Potential and High Dividends - HarianBasis.co
Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co - MarketBeat
ABT: Abbott Laboratories Director Acquires 10,000 Shares Amid De - GuruFocus
AGNC, Lam, Abbott, BlackRock, Schlumberger: Insider Shockwave - TipRanks
Strs Ohio Decreases Stake in Abbott Laboratories $ABT - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT - MarketBeat
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
AI Models Split on Abbott Laboratories (ABT) as Fundamentals Clash With Technical and Valuation Concerns - TipRanks
Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software - Yahoo Finance
Abbott–Exact Sciences, BioMarin–Amicus among deals cleared in Japan in Q1 - MLex
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0 - Yahoo Finance
Abbott Laboratories stock hits 52-week low at $90.72 - Investing.com
Abbott Laboratories stock hits 52-week low at $90.72 By Investing.com - Investing.com Australia
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among C - GuruFocus
Abbott Laboratories (FRA:ABL0) Stock Price, Trades & News - GuruFocus
Abbott Receives FDA Clearance, CE Mark for Ultreon 3.0 AI Imaging Platform - AIM Media House
ABT SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
FDA search for baby formula contamination finds little - Crain's Chicago Business
Abbott Laboratories (ABT) EVP reports 5,314-share trust move - Stock Titan
Vanguard reports 130.7M shares in Abbott Laboratories (ABT) — 7.5% stake - Stock Titan
Ultreon 3.0 regulatory milestone sees Abbott Laboratories stock down 2.64% amid oversold conditions - Traders Union
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Lawsuit Claims Abbott, Boston Scientific SCS Pre-Market Approval Supplements Caused Permanent Injuries - AboutLawsuits.com
Fund Update: 1,400,797 ABBOTT LABORATORIES (ABT) shares added to FLOSSBACH VON STORCH SE portfolio - Quiver Quantitative
Abbott Laboratories Stock: Why Analysts Rate a Buy in 2026 - TIKR.com
Abbott’s Ultreon 3.0 AI Imaging Clearance And What It Means For Valuation - simplywall.st
Abbott’s FDA-Cleared Ultreon 3.0 Redefines Imaging in Coronary Interventions - The Indian Practitioner
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com Canada
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com
Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1 - Yahoo Finance
Major Insider Move Signals Growing Confidence at Abbott Laboratories - TipRanks
Abbott (NYSE: ABT) awards director 2,286 restricted stock units - Stock Titan
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories director Daniel Starks buys $926,537 in shares - Investing.com
Abbott Laboratories director Daniel Starks buys $926,537 in shares By Investing.com - Investing.com India
Abbott Laboratories (NYSE: ABT) director granted 2,286-share RSU award - Stock Titan
[Form 4] ABBOTT LABORATORIES Insider Trading Activity - Stock Titan
Abbott Laboratories (NYSE: ABT) director receives 2,286-share restricted stock unit award - Stock Titan
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.34%
자본화:
|
볼륨(24시간):